Brain Infection Reports Prompt Boxed Warning On Adcetris

Law360, New York (January 13, 2012, 3:34 PM EST) -- Federal regulators said Friday they had slapped a boxed warning on Adcetris — a lymphoma drug developed by Seattle Genetics Inc. and a Takeda Pharmaceutical Co. Ltd. subsidiary — after receiving reports of a rare and potentially deadly brain infection in Adcetris users.

Adcetris is approved for treating Hodgkin lymphoma and another type of lymphoma when chemotherapy and other treatments fail. The U.S. Food and Drug Administration granted accelerated approval of the drug in August, when one case of progressive multifocal leukoencephalopathy, or PML, had been...
To view the full article, register now.